Plain-English translation of NCT06684600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new two-drug combination called dalpiciclib and pyrotinib for people with advanced esophageal squamous cell carcinoma (a type of esophageal cancer) whose cancer has progressed despite first-line chemotherapy. The study hopes to see if this medication combination can slow or stop the cancer from growing when standard treatments are no longer working.
Esophageal cancer is a serious disease that affects many people worldwide, but there is currently no standard second-line treatment option after the initial chemotherapy fails. This trial exists to find out whether this new medication combination can provide hope for patients who need another treatment option.
You likely qualify if…
You likely don't qualify if…
You would take the medication combination by mouth on a regular schedule as an outpatient. You would have regular clinic visits to monitor how well the treatment is working and to check for any side effects through blood tests and imaging scans. The trial aims to enroll about 35 participants total, and you would be part of this group to help researchers understand whether this treatment combination is effective for advanced esophageal cancer.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
China